Critical Contrast: Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Baird Medical Investment (NASDAQ:BDMD)

Baird Medical Investment (NASDAQ:BDMD) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Baird Medical Investment and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Fresenius Medical Care AG & Co. KGaA	5	4	0	0	1.44

Fresenius Medical Care AG & Co. KGaA has a consensus price target of $28.00, suggesting a potential upside of 21.56%. Given Fresenius Medical Care AG & Co. KGaA’s stronger consensus rating and higher possible upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Baird Medical Investment.

Insider & Institutional Ownership

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Baird Medical Investment and Fresenius Medical Care AG & Co. KGaA”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54 million	2.27	N/A	N/A	N/A
Fresenius Medical Care AG & Co. KGaA	$22.20 billion	0.56	$1.11 billion	$1.90	12.12

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Baird Medical Investment.

Profitability

This table compares Baird Medical Investment and Fresenius Medical Care AG & Co. KGaA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%

Risk and Volatility

Baird Medical Investment has a beta of -1.22, indicating that its share price is 222% less volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats Baird Medical Investment on 7 of the 10 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.